title: [Combined interferon-alfa-2b and ribavirin therapy in patients with recurrent chronic hepatitis c after liver transplantation].
abstract: Interferon with ribavirin therapy has been proposed for the treatment of hepatitis C recurring in liver transplants.
  
  
  OBJECTIVE
  Was to assess the efficacy of standard combination therapy (interferon plus ribavirin) of chronic hepatitis C in transplanted patients with recurrent severe HCV induced chronic hepatitis.
  
  
  METHODS
  12 patients with HCV-PCR positive reaction (genotype 1b) were treated with the therapy of interferon-alpha-2b (3 MU three times a week) and 800-1000 mg ribavirin daily. Liver biopsy had been done in every patients before and after the treatment. Study endpoints were the end of treatment and the 6 month post-therapy sustained virologic response.
  
  
  RESULTS
  At the end of treatment 3 patients were negative for HCV-PCR and all of them had negative reaction after 6 month follow-up period.
  
  
  CONCLUSIONS
  The results are in a good accordance with treatment of patients with chronic hepatitis C without liver transplantation.
authors.affiliation: Semmelweis Egyetem, Altalános Orvostudományi Kar, II. Belklinika, Budapest.
authors.forename: Gabriella
authors.initials: G
authors.lastname: Lengyel
authors.forename: László
authors.initials: L
authors.lastname: Kóbori
authors.forename: Imre
authors.initials: I
authors.lastname: Fehérvári
authors.forename: Balázs
authors.initials: B
authors.lastname: Nemes
authors.forename: Dénes
authors.initials: D
authors.lastname: Görög
authors.forename: Attila
authors.initials: A
authors.lastname: Patonai
authors.forename: Enikö
authors.initials: E
authors.lastname: Sárváry
authors.forename: Marina
authors.initials: M
authors.lastname: Varga
authors.forename: Ferenc
authors.initials: F
authors.lastname: Perner
authors.forename: János
authors.initials: J
authors.lastname: Fehér
mesh_terms: D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D000998:Antiviral Agents / Q000627:therapeutic use*; D001219:Aspartate Aminotransferases / Q000097:blood; D001663:Bilirubin / Q000097:blood; D004359:Drug Therapy, Combination; D005260:Female; D019698:Hepatitis C, Chronic / Q000097:blood / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use*; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D012008:Recurrence; D012189:Retrospective Studies; D012254:Ribavirin / Q000627:therapeutic use*; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D012254:Ribavirin; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D001663:Bilirubin